最新ニュース Centene (NYSE:CNC) 株価情報

Centene

Centene is a managed care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of September, mostly in Medicaid (about 60% of membership), the individual exchanges (about 20%), and Medicare Advantage (about 5%). The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program and has a military contract.

Centene Corp

Canna Corp

CHINA NUCLEAR ENERGY TECH by CHINA NUCLEAR ENERGY TECHNOLOGY CORP LTD.

Coincheck Group NV

CANCER CAPITAL CORP by Cancer Capital Corp.

Cancer Capital Corp

CONNECTED MEDIA TECHS INC by Connected Media Technologies, Inc.

Connected Media Technologies Inc

CHUN CAN CAPITAL GROUP by Chun Can Capital Group

Chun Can Capital Group

Core Nickel Corp

CONDUIT CAPITAL LTD ORD by Conduit Capital Ltd.

Range Cancer Therapeutics ETF

CHINA CASTSON 81 FINCE by CHINA CASTSON 81 FINANCE CO.

CHINA TELETECH HLDGS INC by China Teletech Holding, Inc.

CLUSTER GROUP HLDGS LTD by Cluster Group Holdings Limited Co.

Cluster Group Holdings Ltd Co

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">the Senate Finance Committee.</a>
While Kennedy&#8217;s tone in each back-and-forth varied, depending on the senator, it was evident that Kennedy&#8217;s role in the new administration would have a tremendous impact on both pharma and insurance stocks.
<h3 class="wp-block-heading">Drug Price Negotiation</h3>
During one exchange about the high cost of drugs with Senator Catherine Cortez Masto (D-NV), Kennedy said: "Senator, my understanding is that the White House issued an executive order, I believe today, supporting the drug negotiations under the I.R.A. President Trump was very aggressive during his first term about negotiating drug prices."
In reality, Trump has not signed an executive order on the topic since he was sworn into office. A Wednesday news <a href="https://www.cms.gov/newsroom/press-releases/cms-statement-lowering-cost-prescription-drugs" target="_blank" rel="noreferrer noopener">release</a> from the Centers for Medicare and Medicaid Services said that lowering the cost of prescription drugs for Americans &#8220;a top priority&#8221; for the Trump administration and that he would work to improve the transparency of the negotiation process.
Perhaps Kennedy was recalling Trump&#8217;s first term. In 2020, then-45th President Trump <a href="https://www.benzinga.com/general/biotech/20/09/17482940/trump-signs-executive-order-to-lower-us-drug-prices-after-negotiations-with-drugmakers-fail">signed an executive order</a> on U.S. Medicare drug prices intending to reduce costs. Industry leaders, including Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) CEO Albert Bourla, criticized the move. Pfizer was seeking regulatory approval to expand its late-stage vaccine trial at the time.
If Trump signs such an order, it would be a rare show of support from his camp for a Biden-era initiative. In addition to Pfizer, it would also impact major companies like Bristol Myers Squibb, Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) and AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>).
Last month, the Biden administration <a href="https://www.benzinga.com/25/01/43062779/popular-ozempic-wegovy-selected-for-next-round-of-medicare-drug-price-negotiations">identified the next 15 drugs</a> as subject to negotiation. The list included Ozempic and Wegovy — two expensive drugs for diabetes and obesity owned by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
See Also: <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">RFK Jr. Is A &#8216;Predator&#8217; Unfit For Office, Caroline Kennedy Says </a>
<h3 class="wp-block-heading">Insurance Providers</h3>
According to the <a href="https://www.nytimes.com/live/2025/01/29/us/rfk-jr-health-senate-hearing">New York Times</a>, Kennedy wasn&#8217;t exactly familiar with Medicare and Medicaid, but expressed support for Medicare Advantage, where private insurers provide coverage for elderly Americans.
Kennedy also called out what he considered to be &#8220;rapacious behavior by insurance companies." He even suggested he would support some of the efforts undertaken during the Biden administration to crack down on abusive tactics like denying care and overcharging the government.
Traders would be wise to keep an eye on how insurance stocks — especially those tied to Medicaid and Medicare providers — react if Kennedy is sworn in. The major players in this space include: 
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer in the U.S.; Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>); Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid managed care organizations; Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>); CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>); Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>); and Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>).
What&#8217;s Next: Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
The title also puts him in charge of the Food and Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.
He will appear before the Senate Committee on Health, Education Labor and Pensions on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/43216758/well-go-as-far-as-im-allowed-trumps-plan-with-immigrants-starts-with-1-million-deportations" target="_blank" rel="noreferrer noopener">‘We'll Go As Far As I'm Allowed': Trump's Plan With Immigrants Starts With 1 Million Deportations</a></li>
</ul>
Image: Shutterstock

Health Care

Politics

Insurance

ABBV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 18.61%. Currently, Centene has a market capitalization of $32.14 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $13,092.03 today based on a price of $63.66 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737497710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much Today

Rumors

Watching Centene; Traders Circulate Unconfirmed Rumor That David Einhorn Has Established A New Position In The Co

Shares of insurance and pharmacy benefit manager (PBM) companies such as Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) and CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) are trading lower Thursday, likely in reaction to UnitedHealth Group Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) disappointing fourth-quarter 2024 revenue results.
What To Know: UnitedHealth, the largest health insurer in the U.S., reported a revenue increase of 6.8% year-over-year to $100.8 billion, falling short of the consensus estimate of $101.76 billion.
UnitedHealth&#8217;s stock declined sharply, falling 6.04% to $510.59, as the earnings report highlighted concerns over its medical care ratio, which rose to 85.5% from 83.2% in 2023. This increase was attributed to factors such as Medicare funding reductions, member mix changes and the timing of Medicaid redeterminations.
UnitedHealth also reaffirmed its 2025 guidance, projecting $450 billion to $455 billion in revenue and adjusted EPS of $29.50 to $30.00.
The broader sector saw a ripple effect. The declines potentially reflect investor apprehension about sector-wide pressures, including reimbursement challenges and operational costs, spotlighted by UnitedHealth&#8217;s earnings report.
Price Actions: Closing Thursday, Centene stock dropped 0.44% to $62.87, CVS Health slid 0.15% to $51.96, Elevance Health fell 1.03% to $385.26 and Humana dropped 1.62% to $274.97 according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/01/43039835/dave-ramsey-breaks-down-how-a-40000-car-depreciates-by-16000-over-5-years-says-its-not-a-path-to-prosperity-even-on-an-80000-salary">Dave Ramsey Breaks Down How A $40,000 Car Depreciates By $16,000 Over 5 Years, Says It&#8217;s Not A Path To Prosperity, Even On An $80,000 Salary</a></li>
</ul>
Photo: Shutterstock.

Movers

Insurance, Pharmacy Benefit Manager Company Stocks Drop Following UnitedHealth's Q4 Revenue Miss: What's Going On?

WIIM

Shares of insurers and pharmacy benefit manager stocks are trading lower in possible reaction to UnitedHealth's quarterly revenue miss.

Shares of health insurers are trading higher after The Centers for Medicare & Medicaid Services proposed a rise to Medicare Advantage payments.

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 5.77% on an annualized basis producing an average annual return of 17.46%. Currently, Centene has a market capitalization of $30.59 billion. 
Buying $100 In CNC: If an investor had bought $100 of CNC stock 15 years ago, it would be worth $1,117.05 today based on a price of $60.60 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735334113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Centene Stock In The Last 15 Years

Centene's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) short percent of float has risen 7.58% since its last report. The company recently reported that it has 16.31 million shares sold short, which is 3.69% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Centene Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734703224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Centene has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Centene's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Centene's peer group average for short interest as a percentage of float is 5.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

(CNC) - Analyzing Centene's Short Interest

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Biotech

Government

General

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 5.53% on an annualized basis producing an average annual return of 17.18%. Currently, Centene has a market capitalization of $30.04 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $10,701.64 today based on a price of $59.50 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734625810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JP Morgan analyst John Stansel assumes Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight rating and lowers Price Target of $75.

Price Target

Initiation

Analyst Ratings

JP Morgan Assumes Centene at Overweight, Lowers Price Target of $75

Centene shares are trading higher after the UBS upgraded the stock from Neutral to Buy and raised its price target from $79 to $80. Also, Barclays maintained an Overweight rating on the stock and raised its price target from $91 to $93.

Stephens &amp; Co. analyst Scott Fidel maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Equal-Weight and lowers the price target from $75 to $73.

Stephens & Co. Maintains Equal-Weight on Centene, Lowers Price Target to $73

Truist Securities analyst Ryan MacDonald maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Buy and lowers the price target from $89 to $84.

Truist Securities Maintains Buy on Centene, Lowers Price Target to $84

Barclays analyst Andrew Mok maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and raises the price target from $91 to $93.

Barclays Maintains Overweight on Centene, Raises Price Target to $93

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wolfe Research analyst Darrin Peller upgraded the rating for PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) from Peer Perform to Outperform and announced a $107 price target. PayPal shares closed at $89.40 on Thursday. See how other analysts view this stock.</li>
<li>B of A Securities analyst Tal Liani upgraded Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) from Neutral to Buy and raised the price target from $70 to $95. Ciena shares closed at $84.52 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Kyle Peterson upgraded Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) from Hold to Buy and announced a $100 price target. Upstart shares closed at $77.08 on Thursday. See how other analysts view this stock.</li>
<li>UBS analyst A.J. Rice upgraded the rating for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Buy and increased the price target from $79 to $80. Centene shares closed at $58.00 on Thursday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Stephen Baxter upgraded the rating for Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) from Underweight to Equal-Weight and raised the price target from $101 to $127. Cardinal Health shares closed at $117.46 on Thursday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PYPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="622" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png" alt="" class="wp-image-691544" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-1024x622.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-300x182.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115-768x466.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13094920/image-115.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42460676/jim-cramer-amd-ceo-lisa-su-built-an-amazing-company">Jim Cramer Says This CEO &#8216;Built An Amazing Company,&#8217; Recommends Buying Netflix</a></li>
</ul>

Upgrades

Markets

CIEN

PYPL

UPST

This PayPal Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Oppenheimer analyst Michael Wiederhorn maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $95 to $85.

Oppenheimer Maintains Outperform on Centene, Lowers Price Target to $85

UBS analyst A.J. Rice upgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Neutral to Buy and raises the price target from $79 to $80.

UBS Upgrades Centene to Buy, Raises Price Target to $80

I admit it: I am something of a geek.
I spend a lot of time sitting around reading articles, crunching numbers, and engaging in other research-focused activities.
One of my favorite ways to spend an afternoon is with a game in the background (preferably baseball, but there has to be an offseason), reading the latest academic studies and insights.
Recently, I spent some time with a study on insider buying titled &#8220;Are CFOs&#8217; Trades More Informative Than CEOs&#8217; Trades?&#8221;
As it turns out, they are.
Everyone focuses on the CEO. After all, he is the top executive who sees everything: all the plans, all the ideas, all the sales figures, everything.
The CEO is the ship&#8217;s captain who sees all and theoretically knows all.
Why, then, does the CFO outperform?
Keeping our ship analogy, the CEO may be the captain, but the CFO oversees the engine room and the power plant.
He knows what cash is coming in, where it is going, and how the excess is being spent.
The CFO knows how much they owe and to whom they owe it.
The CFO is also present in every meeting and sees every plan and vision laid out by the CEO and other executives.
He also knows how these plans will impact the business&#8217;s financial health.
She is also best positioned to judge how these plans will likely impact the company&#8217;s value.
When the Chief Financial Officer buys, it is because the business is trading for less than the ultimate insider view says it is worth.
Here are three companies with recent significant buying by the Chief Financial Officer:
Dorchester Minerals, L.P. (Ticker: DMLP) is a master limited partnership that acquires, owns, and manages producing and non-producing mineral, royalty, overriding royalty, net profits, and leasehold interests across the United States.
Its diversified portfolio spans 593 counties and parishes in 28 states, providing exposure to various oil and gas assets.
While the company is currently most active in the Permian and Bakken regions, it also has significant acreage in the Utica Shale and Marcellus Shale regions, which hold enormous amounts of natural gas.
Most energy industry insiders think that natural gas will be in huge demand as the energy source for developing AI to its full potential.
As a royalty trust, Dorchester is paid for every drop of oil and gas produced on the acreage they own. At the current price, the yield on the shares is over 10%.
CFO Leslie Moriyama is clearly a big believer in higher energy prices, as she has recently purchased over $500,000 worth of additional stock in the company.
HA Sustainable Infrastructure Capital, Inc. (Ticker: HASI), formerly known as Hannon Armstrong Sustainable Infrastructure Capital, Inc., is a leading investor in climate solutions, focusing on energy efficiency, renewable energy, and other sustainable infrastructure markets across the United States.
HA Sustainable Infrastructure Capital, Inc. (HASI) maintains a diversified portfolio across three primary markets: Behind-the-Meter (BTM), Grid-Connected (GC), and Fuels, Transport &amp; Nature (FTN). As of June 30, 2024, the portfolio distribution was approximately 47% in BTM, 40% in GC, and 13% in FTN.
The company&#8217;s investments encompass various asset classes, including equity, joint ventures, land ownership, lending, and other financing transactions. Notable investments include a structured equity investment in a 2.0 GW portfolio of contracted wind, solar, and solar-plus-storage projects, and a senior debt investment in a portfolio of operating landfill gas-to-renewable natural gas and wastewater treatment biogas-to-renewable natural gas plants.
CFO Marc Pangburn is not buying the death of renewables story, as he recently purchased a six-figure stake in the company.
Centene Corporation (Ticker: CNC), headquartered in St. Louis, Missouri, is a leading managed care company specializing in government-sponsored healthcare programs. Founded in 1984, Centene has become a significant intermediary for government-sponsored and privately insured healthcare plans, offering a comprehensive range of services to individuals and families across the United States. The company&#8217;s portfolio includes Medicaid, Medicare Advantage, and Marketplace insurance plans, serving over 28 million members nationwide.
In the third quarter of 2024, Centene reported total revenues of $42.0 billion, marking a 10% increase from the same period in the previous year. This growth was primarily driven by a 22% increase in Marketplace membership and a 49% rise in Medicare Prescription Drug Plans. The company&#8217;s adjusted diluted earnings per share stood at $1.62, surpassing analysts&#8217; expectations.
Despite a decline in Medicaid membership due to redeterminations, Centene&#8217;s diversified portfolio allowed it to navigate these challenges effectively. The company reaffirmed its full-year adjusted diluted EPS guidance of greater than $6.80, reflecting confidence in its financial outlook.
The stock has sold off this year, finally attracting the interest of CFO Andrew Asher, who recently purchased $1 million worth of the company.

Opinion

DMLP

Hannon Armstrong Sustainable Infrastructure Capital

HASI

C-Suite Buy of the Week: Executives' Investments Offer Clues to Market Directions

On Thursday, Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) outlined its 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42456151/centene-corporation-announces-2025-guidance" rel="noreferrer noopener">financial guidance</a>.
For fiscal year 2025, the health insurance plan provider expects total revenues of&nbsp;$166.5 billion&nbsp;to&nbsp;$169.5 billion, compared to a consensus of $166.58 billion.
The guidance includes premium and service revenues of&nbsp;$154.0 billion&nbsp;to&nbsp;$156.0 billion. The company expects GAAP EPS of greater than&nbsp;$6.19, with adjusted EPS of greater than&nbsp;$7.25 compared to the consensus of $6.97.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The company expects a Health benefits ratio (HBR) of 88.4% to 89.0%.
The insurer forecasts a 2025 selling, general, and administrative (SG&amp;A) expense ratio of 8.1% to 8.7%, with an adjusted SG&amp;A expense ratio of 8.1% to 8.7%.
The company reaffirms its 2024 premium and service revenues guidance if&nbsp;$143.5 billion&nbsp;to&nbsp;$144.5&nbsp;billion, HBR guidance if 88.3% to 88.5%, and adjusted diluted EPS guidance <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41542651/centene-says-it-is-positioned-to-capture-long-term-growth-in-government-sponsored-healthcare-lifts-" rel="noreferrer noopener">of greater than&nbsp;$6.80</a>.
&#8220;Centene is a mission driven organization, dedicated to delivering high quality outcomes for more than 28 million members, many of whom are among the nation&#8217;s most medically complex and historically underserved populations. Over the last three years we improved our core operations and invested in the experience of our customers and providers, all while delivering on our financial commitments,&#8221; said Chief Executive Officer of Centene,&nbsp;Sarah London.
Full-year 2024 earnings will be reported on February&nbsp;4, 2025.
Price Action: CNC stock is up 1.92% at $57.99 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42462096/keros-therapeutics-pauses-two-treatment-arms-in-mid-stage-hypertension-trial-stock-plummets" target="_blank" rel="noreferrer noopener">Keros Therapeutics Loses 75% Value In A Single Session &#8211; Here&#8217;s Why</a></li>
</ul>

Earnings

Large Cap

Guidance

Why Is Insurance Firm Centene Stock Trading Higher On Thursday?

Centene, CNH Industrial new positions at Greenlight - Q4 letter

Centene, CNH Industrial positions discussed in Greenlight Q4 letter

CNH Industrial gains as Greenlight letter mentions; added to Capri position (update)

In its quarterly letter to investors, David Einhorn's Greenlight Capital disclosed that the firm established a new "medium-sized position" in CNH I...

Greenlight started 'medium-sized' CNH position, 'small' position in Centene

Greenlight Capital Q4 2024 Letter

Elevance sends Medicaid insurers higher after Q4 revenue beat

Managed Care Insurers Get Wall Street Bump Even With Mixed Q4 2024 Results

In a memo dated January 27 from Matthew Vaeth, Acting Director, Office of Management and Budget, sent to the heads of the federal government's exec...

Medicaid insurers slip as Trump administration pauses assistance program payouts

Early Tuesday, the White House budget office circulated a 52-page document as it seeks to implement a sweeping freeze of federal assistance, orderi...

Comments

Centene

ニュース

最新ニュース Centene (NYSE:CNC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル